Getting started with in-house development: storyboarding
Introducing our three-part blog series on getting started with in-house development. In this series, we’re…
Certara2020 年 2 月 21 日
Getting started with in-house development: how does it work?
Introducing our three-part blog series on getting started with in-house development. In this series, we’re…
Certara2020 年 2 月 10 日
ICER’s Unsupported Drug Price Increase Report: An Analysis
We analyze the drug-price watchdog, ICER’s (Institute for Clinical and Economic Review) “Report on Unsupported…
Certara2019 年 10 月 24 日
Introducing P21 Community 3.0
2019 年 5 月 7 日 We are thrilled to announce that P21 Community 3.0 is available for immediate…
Certara2019 年 5 月 7 日
New Pinnacle 21 Enterprise 4.0 Eases Concern about PMDA Submissions
2019 年 4 月 2 日 Released March 31, the new P21 Enterprise 4.0 provides more options for…
Certara2019 年 4 月 2 日
What’s New in Enterprise 3.4 Q&A
Is there documented guidance on the creation of the sponsor SDTM metadata to be uploaded…
Certara2018 年 5 月 17 日
Pinnacle 21 Wins TOPRA Award for Regulatory Excellence in Innovation
Certara’s Pinnacle 21 is honored to announce that Max Kanevsky, has been named to the…
Certara2016 年 12 月 1 日
More Power to OATP1B1: An Evaluation of Sample Size in Pharmacogenetic Studies Using a Rosuvastatin PBPK Model for Intestinal, Hepatic, and Renal Transporter-mediated Clearances
Rosuvastatin is a substrate of choice in clinical studies of organic anion-transporting polypeptide (OATP)1B1- and…
Danielle Pillsbury2016 年 7 月 1 日
Development of a Permeability-limited Model of the Human Brain and Cerebrospinal Fluid (CSF) to Integrate Known Physiological and Biological Knowledge: Estimating Time Varying CSF Drug Concentrations and Their Variability Using In Vitro Data
A 4-compartment permeability-limited brain (4Brain) model consisting of brain blood, brain mass, cranial and spinal…
Danielle Pillsbury2016 年 6 月 1 日
